Phase III clinical trial assessing R-phenserine in patients with Parkinson's disease
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Buntanetap (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Annovis Bio
- 27 Jun 2022 According to an Annovis Bio media release, the company put first parkinson patient in this trial in May, June.
- 09 Jun 2022 According to an Annovis Bio media release, company expects to start recruitment this summer.
- 05 Jan 2022 According to Annovis Bio medoia release, the Company expects guidance from the U.S. Food and Drug Administration (FDA) in Q1 of 2022 on the initiation of this phase 3 clinical trial.